CIMG unit agrees $40M share-based Daren acquisition tied to aggressive 3.5-year revenue milestones

CIMG subsidiary structures $40 million share‑based purchase tied to Daren revenue milestones

CIMG Inc.’s wholly owned unit DZR Tech Limited agrees to acquire Daren Business Technology Limited under a performance‑based share consideration that ties most of the payment to audited revenue targets over a 3.5‑year assessment period. The deal, signed on Feb. 5, 2026, calls for the aggregate purchase consideration to be paid in CIMG shares held in escrow with an approximate aggregate value of $40 million and released in four phases from April 2026 through September 2029. Release ratios are set at 6%, 14%, 28% and 52% for each phase respectively, and unreleased shares are cancelled if targets are not met.

The arrangement specifies minimum audited revenue thresholds for each assessment window: at least $29 million for April 1–Sept. 30, 2026; $71 million for Oct. 1, 2026–Sept. 30, 2027; $143 million for Oct. 1, 2027–Sept. 30, 2028; and $257 million for Oct. 1, 2028–Sept. 30, 2029. The agreement permits adjustments to both the value and number of escrowed shares to account for performance variances, with cumulative excess performance available to offset prior shortfalls. Closing is subject to customary conditions and satisfactory due diligence and is expected to occur within 30 days of the agreement.

CIMG and Daren build in mechanisms to align incentives and limit immediate cash outflow, effectively making the bulk of the purchase contingent on Daren meeting aggressive growth benchmarks. The phased escrow and cancellation provisions mean the majority of consideration is conditional, while the ability to offset shortfalls with later outperformance provides a pathway for full payment if Daren significantly exceeds targets.

Daren’s capabilities and closing timetable

Daren is described as a high‑tech biomedicine enterprise integrating research and development, production, marketing and technical services, with capabilities in R&D, quality control and supply‑chain management. The parties anticipate closing within the 30‑day window if due diligence and customary conditions are satisfied, after which the escrowed shares begin to be eligible for phased release in April 2026.

Strategic implications for CIMG

The transaction expands CIMG’s exposure to biomedicine product development and downstream supply‑chain operations through its DZR Tech unit while keeping near‑term cash impact limited. The structure transfers execution risk to Daren’s post‑closing performance, aiming to align seller incentives with CIMG’s growth objectives but also embedding the risk that ambitious revenue targets may not be met.